Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2− metastatic breast cancer
Crossref DOI link: https://doi.org/10.1007/s00228-024-03715-4
Published Online: 2024-06-20
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Pan, Meiyu
Lin, Yan
Liu, Yinhui
Xu, Ruijuan
Yang, Jin
Text and Data Mining valid from 2024-06-20
Version of Record valid from 2024-06-20
Article History
Received: 25 March 2024
Accepted: 13 June 2024
First Online: 20 June 2024
Declarations
:
: The authors declare no competing interests.